Avatar Posted by worldpharmanews 691 days ago (http://www.worldpharmanews.com)
Category: Product | Tags: emea angiotensin ii
The European Medicines Agency (EMEA) has recommended that the product information of all centrally authorised angiotensin II receptor antagonists be harmonised, regarding their use during pregnancy. Following a review of the safety of these medicines during pregnancy, the EMEA's Committee for Medicinal Products for Human Use (CHMP), at its April 2008 meeting, recommended that the product information should state that the use of angiotensin II receptor antagonists should be avoided in the first three months of pregnancy.
Discuss   Add this link to...  Bury

Comments Who Voted Related Links


News/Blogroll [ alliConnect | BioJobBlog | Central and Eastern Europe Pharma | CNTO411 | Corey Nahman | eDrugSearch | Drug Injury Watch | EyeOnFDA | Forbes ScienceBiz | Healthy Skepticism | JNJ BTW | medGadget | Medical 2.0 | Pharma's Market at CNBC | PharmaFraud | PharmaGossip | Pharmalot | PharmaNews.eu | Polish Pharma Market | The Shark Report | World Pharma News | WSJ Health Blog ]
Pharmaceutical Companies [ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

About | Buttons | Contact | Terms and Conditions
Concept and Design by World Pharma News (.com) Project | Powered by Pligg based on PHP/MySQL.
Submit to World Pharma News .net